533 656
As part of their strategy to address appropriate health
care provision to the growing elderly population, the
European Union adopted a communication in 2012
[5,6]for which funding was provided through European
Commission funding programmes (initially FP7, and con-
tinued through Horizons2020). Innovative trial models
involving all relevant stakeholders, including patients and
industry, addressing the inclusion of patients with multiple
morbidities are under development
[7].
Conflicts of interest:
The authors have nothing to disclose.
References
[1] UN Population Division. World population prospects: the 2015
revision. United Nations; 2015.
https://esa.un.org/unpd/wpp/[2] EUROSTAT. Statistics in focus. March 1999.
http://ec.europa.eu/ eurostat/documents/3433488/5278217/CA-DN-99-004-EN.PDF/ 0f91fe65-e0ce-4948-8c2f-7d8ad48c9f64.
[3]
Droz J-P, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017;72: 521–31.
[4]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618–29.
[5]
European Commission. Taking forward the strategic implementa- tion plan of the European Innovation Partnership on Active and Healthy Ageing. Communication from the Commission to the European Parliament and the Council. Brussels, Belgium: European Commission; 2012. p. 16.[6] European Commission. Growing the European silver economy.
http://ec.europa.eu/research/innovation-union/pdf/active- healthy-ageing/silvereco.pdf .[7]
Committee for Medicinal Products for Human Use. Points to con- sider on frailty: evaluation instruments for baseline characterisa- tion of clinical trial populations. London, UK: European Medicines Agency; 2015. p. 18.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 3 2 – 5 3 3
533